adalimumab-aaty (Yuflyma) vs infliximab-qbtx (Ixifi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-aaty (Yuflyma)

Marketed by Celltrion

Approved in Rheumatoid Arthritismonoclonal antibody
Partial signal

NCT03789292 · Phase 3 · completed

This randomized, double-blind Phase 3 equivalence trial compared CT-P17 (Yuflyma) with EU-approved Humira in 648 adults with active rheumatoid arthritis. The primary endpoint was ACR20 response at week 24, and equivalence required the confidence interval of the difference to fall inside predefined margins. ACR20 response was 82.7% in both groups; the 95% CI (-5.94 to 5.94) and the 90% CI (-4.98 to 4.98) were inside the margins, so equivalence was shown and the primary endpoint was met. Source: the peer-reviewed trial report (Kay 2021).

Reported efficacy

American College of Rheumatology(ACR)20 Response Rate at Week 24.: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther). (met)

Result source: NCT03789292

infliximab-qbtx (Ixifi)

Marketed by Pfizer

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02222493 · Phase 3 · completed

This was a randomized, quadruple-blinded, active-controlled Phase 3 equivalence trial in 650 adults with rheumatoid arthritis taking methotrexate, comparing PF-06438179 with infliximab. The primary endpoint was ACR20 response at Week 14, a clinical disease-activity measure: 61.1% with PF-06438179 versus 63.5% with infliximab, and the reported 95% confidence interval for the difference (-9.92 to 5.11) met the equivalence criterion, indicating no meaningful difference between treatments. This is strong evidence from a well-powered, blinded, controlled trial with a hard clinical endpoint and a met primary comparison.

Reported efficacy

Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%) (met)

Result source: NCT02222493

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-aaty (Yuflyma)infliximab-qbtx (Ixifi)
ACR2082.7% vs 82.7%vs Humirawk 24 · n 324NCT0378929261.1% vs 63.5%vs Infliximab-EU Remicade (INX)wk 14 · n 324NCT02222493
12 other results
  • 71.1% vs 64.3% wk 54 · n 280 · Phase 3 · secondary NCT02222493
  • 70.6% vs 64.3% wk 54 · n 143 · Phase 3 · secondary NCT02222493
  • 71.1% vs 68.5% wk 46 · n 280 · Phase 3 · secondary NCT02222493
  • 69.2% vs 68.5% wk 46 · n 143 · Phase 3 · secondary NCT02222493
  • 73.6% vs 70.6% wk 38 · n 280 · Phase 3 · secondary NCT02222493
  • 76.9% vs 70.6% wk 38 · n 143 · Phase 3 · secondary NCT02222493
  • 60.8% vs 64.1% wk 30 · n 324 · Phase 3 · secondary NCT02222493
  • 63.3% vs 65.3% wk 22 · n 324 · Phase 3 · secondary NCT02222493
  • 64.8% vs 65.6% wk 12 · n 324 · Phase 3 · secondary NCT02222493
  • 57.7% vs 61.7% wk 6 · n 324 · Phase 3 · secondary NCT02222493
  • 52.5% vs 58.3% wk 4 · n 324 · Phase 3 · secondary NCT02222493
  • 32.4% vs 37.1% wk 2 · n 324 · Phase 3 · secondary NCT02222493
ACR50—Not reported—Not reported
ACR70—Not reported—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-aaty (Yuflyma)
82.7% vs 82.7%vs Humirawk 24 · n 324NCT03789292
infliximab-qbtx (Ixifi)
61.1% vs 63.5%vs Infliximab-EU Remicade (INX)wk 14 · n 324NCT02222493
12 other results
  • 71.1% vs 64.3% wk 54 · n 280 · Phase 3 · secondary NCT02222493
  • 70.6% vs 64.3% wk 54 · n 143 · Phase 3 · secondary NCT02222493
  • 71.1% vs 68.5% wk 46 · n 280 · Phase 3 · secondary NCT02222493
  • 69.2% vs 68.5% wk 46 · n 143 · Phase 3 · secondary NCT02222493
  • 73.6% vs 70.6% wk 38 · n 280 · Phase 3 · secondary NCT02222493
  • 76.9% vs 70.6% wk 38 · n 143 · Phase 3 · secondary NCT02222493
  • 60.8% vs 64.1% wk 30 · n 324 · Phase 3 · secondary NCT02222493
  • 63.3% vs 65.3% wk 22 · n 324 · Phase 3 · secondary NCT02222493
  • 64.8% vs 65.6% wk 12 · n 324 · Phase 3 · secondary NCT02222493
  • 57.7% vs 61.7% wk 6 · n 324 · Phase 3 · secondary NCT02222493
  • 52.5% vs 58.3% wk 4 · n 324 · Phase 3 · secondary NCT02222493
  • 32.4% vs 37.1% wk 2 · n 324 · Phase 3 · secondary NCT02222493

ACR50

adalimumab-aaty (Yuflyma)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

ACR70

adalimumab-aaty (Yuflyma)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

DAS28-CRP remission

adalimumab-aaty (Yuflyma)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

HAQ-DI, change

adalimumab-aaty (Yuflyma)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported

Modified Sharp score, change

adalimumab-aaty (Yuflyma)
—Not reported
infliximab-qbtx (Ixifi)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-aaty (Yuflyma): 4 of 4 rows · infliximab-qbtx (Ixifi): 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-aaty (Yuflyma)infliximab-qbtx (Ixifi)
Dropout rate
6.5%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
—Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Discontinued due to AEs
2.2%CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
—Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
—Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
—Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Serious AEs
—CT-P17 Subcutaneous(SC) (Adalimuma
NCT03789292 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 4 more results
—Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.7%Treatment 1: CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
2%Treatment 2: CT-P17 Maintenance
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
3.3%Treatment 2: Switched to CT-P17
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
5%Period 1: PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
2.8%Period 2: INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
4.6%Period 2: PF-06438179/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
2.4%Period 3: INX/INX/PF-06438179
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
4.8%Period 3: INX/PF-06438179/PF-06438
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
1.2%Period 3: PF-06438179/PF-06438179/
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
Most frequent reported AEs
upper respiratory tract infection 5.6%
nasopharyngitis 5.2%
injection site reaction 4.9%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
neutropenia 5%
upper respiratory tract infection 3.3%
urinary tract infection 3%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
neutropenia 5.3%
alanine aminotransferase increased 4.6%
leukopenia 4.6%
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 5.9%
infusion related reaction 5.9%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
show 5 more results
infusion related reaction 4.2%
alanine aminotransferase increased 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
infusion related reaction 2.9%
alanine aminotransferase increased 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3
alanine aminotransferase increased 0%
infusion related reaction 0%
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-aaty (Yuflyma)

DAS28-CRP -2.738 vs -2.734 Humira score @ 24wk
absolute change · score
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
-2.945 vs -3.074 Humira score @ 52wk
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.983 vs -3.074 Humira score @ 52wk
NCT03789292 · Phase 3 · Rheumatoid Arthritis · phase 3

infliximab-qbtx (Ixifi)

ACR20 78.7% (n=253) @ 62wk
responder rate · % of participants
No placebo or comparator arm
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 199 participants as posted
show 8 more results
70.6% (n=126) @ 62wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 89 participants as posted
81.7% (n=126) @ 62wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 103 participants as posted
78.7% (n=253) @ 70wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 199 participants as posted
69% (n=126) @ 70wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 87 participants as posted
77.8% (n=126) @ 70wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted
75.9% (n=253) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 192 participants as posted
68.3% (n=126) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 86 participants as posted
77.8% (n=126) @ 78wk*
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 98 participants as posted
ACR50 7.4% (n=324) vs 7.4% (n=326) Infliximab-EU Remicade (INX) @ 2wk
responder rate · % of participants
ACR50 (Week 2)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 24 participants as posted
ACR50 22.2% (n=324) vs 18.1% (n=326) Infliximab-EU Remicade (INX) @ 4wk
responder rate · % of participants
ACR50 (Week 4)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 72 participants as posted
ACR50 27.2% (n=324) vs 24.5% (n=326) Infliximab-EU Remicade (INX) @ 6wk
responder rate · % of participants
ACR50 (Week 6)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 88 participants as posted
ACR50 29.3% (n=324) vs 31% (n=326) Infliximab-EU Remicade (INX) @ 12wk
responder rate · % of participants
ACR50 (Week 12)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 95 participants as posted
ACR50 35.8% (n=324) vs 33.1% (n=326) Infliximab-EU Remicade (INX) @ 14wk
responder rate · % of participants
ACR50 (Week 14)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 116 participants as posted
ACR50 38.9% (n=324) vs 35.6% (n=326) Infliximab-EU Remicade (INX) @ 22wk
responder rate · % of participants
ACR50 (Week 22)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 126 participants as posted
ACR50 38.6% (n=324) vs 40.5% (n=326) Infliximab-EU Remicade (INX) @ 30wk
responder rate · % of participants
ACR50 (Week 30, pre-dose)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 125 participants as posted
ACR70 1.9% (n=324) vs 1.8% (n=326) Infliximab-EU Remicade (INX) @ 2wk
responder rate · % of participants
ACR70 (Week 2)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 6 participants as posted
ACR70 6.8% (n=324) vs 4% (n=326) Infliximab-EU Remicade (INX) @ 4wk
responder rate · % of participants
ACR70 (Week 4)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 22 participants as posted
ACR70 10.2% (n=324) vs 4.9% (n=326) Infliximab-EU Remicade (INX) @ 6wk
responder rate · % of participants
ACR70 (Week 6)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 33 participants as posted
ACR70 14.2% (n=324) vs 12.3% (n=326) Infliximab-EU Remicade (INX) @ 12wk
responder rate · % of participants
ACR70 (Week 12)
NCT02222493 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 · converted to % from 46 participants as posted

+ 41 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-aaty (Yuflyma)'s landscape · infliximab-qbtx (Ixifi)'s landscape